XPO1 and central nervous system cancer: The irreversible inhibitor of CRM1, KPT-330, also exerts anti-tumor activity in preclinical models of glioblastoma [37], but the molecular mechanism and cellular signaling pathways mediating the anti-glioma activity of KPT-330 remain unknown.